About usOur team
Our science
Our pipeline
News
Investors
Contact us
About usOur team
Our science
Our pipeline
News
Investors
Contact us

News

ASX Releases

May 29, 2023

FDA Pre-IND Meeting Supports an IND Application for RAD101

Read moreRead more
May 9, 2023

RAD Receives FDA Orphan Drug Designation for Trivehexin (RAD301) in Pancreatic Cancer

Read moreRead more
April 17, 2023

RAD Enters into Supply Agreement with Terthera for Terbium-161 Isotope

Read moreRead more
March 28, 2023

RAD Invited to Participate in Jefferies Radiopharma Innovation Summit

Read moreRead more
March 28, 2023

RAD Receives $1.56M R&D Tax Incentive

Read moreRead more
March 27, 2023

RAD and GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia

Read moreRead more

MEDIA releases

May 2, 2023

Positive new publication for RAD301 platform

Read moreRead more
February 21, 2023

FNN Interview with CEO about RAD's ambition to list on Nasdaq

Read moreRead more
February 16, 2023

Investor Webinar

Read moreRead more
February 14, 2023

RAD CEO interview with Proactive Investors and announcement of Nasdaq listing initiation

Read moreRead more
December 1, 2022

GenesisCare and RAD Partner to Bring World First Novel Radiopharmaceuticals to Australian Cancer Patients

Read moreRead more
October 6, 2022

CEO Interview series with Wholesale Investor

Read moreRead more

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.
About usOur teamRadiopharmaceuticals
Our technologyAbstracts & publicationsOur pipeline
NewsInvestorsPrivacy Policy
Contact us+61 3 9824 5254info@radiopharmtheranostics.com
© Copyright 2023 | All Rights Reserved
Site by Charles Lloyd